MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the second half of 2025. First quarter 2025 revenues were reported at $78 million, with a non-GAAP net income of $22 million. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.